Latest Articlesddd
The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …
CRISPR Therapeutics' (CRSP) stock added around $8 today while reporting financial results for the fourth quarter …
We congratulate our subscribers who kept Spark Therapeutics (ONCE) in spite of the stock’s kind of paralysis for no …
Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil, the firm’s potential treatment for heart failure with reduced ejection fraction, …
Keytruda and Cabometyx Are Both Winners Keytruda failed to meet co-primary endpoints in Pivotal Phase 3 …
From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …
Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at …
RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor …
Exelixis’ (EXEL) financial results for the fourth quarter and full year 2018 are as inspiring as they are …
Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® in …
The United States FDA granted Breakthrough Therapy Designation to AMT-061. The European Medicines Agency gave it …
Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …
ImmunoGen & Biogen News About ImmunoGen ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) …
Halozyme Therapeutics (HALO) and argenx (ARGX) announced a global collaboration and license agreement offering argenx the right to use …
FDA Granted Rare Pediatric Disease Designation for RegenxBio’s Product RGX-181 for CLN2 RegenxBio RegenxBio (RGNX), a …
Merck (MRK) announced its Q4 2018 financial results. The firm outperformed itself and delighted us with regard …
AGENUS Agenus (AGEN) announced the upcoming launch of its Biotech Electronic Security Token (BEST); the first digital security …
Can a liquid biopsy test be accurate enough for physicians to rely on in differentiating between …
Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …
Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
